Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2015, 24(4):226-229

Role of sympathetic nervous system in the pathophysiology of resistant hypertension

Škultétyová D
Klinika kardiológie a angiológie, Národný ústav srdcových a cievnych chorôb, a.s., Bratislava, Slovenská republika

The pathogenesis of hypertension is complex and multifactorial. Increased sympathetic nervous system (SNS) activity has been documented in all hypertension stages, the more advanced the stage, the greater the adrenergic activity. The excessive SNS activity plays a crucial role in the development of resistant hypertension (RH). The autonomic NS can modulate innate and adaptive immunity and thereby influence the inflammatory response. The sympathoexcitation and the neuro-immune pathways may increase the initiation or acceleration of pathological processes. Obesity and salt sensitivity are important environmental risk factors in hypertension. Both factors are considered to play a major role in the brain and renal sympathoexcitation. Targeting the brain to reduce enhanced sympathetic activity should be considered in the treatment for hypertension. Novel techniques, such as catheter-based renal denervation and carotid baroreflex activation therapy, are suggested to reduce central and renal sympathetic otflow.

Keywords: autonomic nervous system; neuro-immune axis; inflammation; catheter-based renal denervation; carotid baroreflex activation therapy

Published: April 1, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Škultétyová D. Role of sympathetic nervous system in the pathophysiology of resistant hypertension. Cardiology Letters. 2015;24(4):226-229.
Download citation

References

  1. Filipová S, Dukát A, Škultétyová D. Aký je prínos nových odporúčaní pre diagnostiku a liečbu hypertenzie? Komentár k 2013ESH/ESC Odporúčaniam pre manažment artériovej hypertenzie. Cardiology Lett. 2014;23:5-9.
  2. Oliva RV, Bakris GL. Sympathetic activation in resistant hypertension: Theory and Therapy. Semin nephrol. 2014;34:550-559. Go to original source...
  3. Larsen R, Thorp A, Schlaich M. Regulation of the sympathetic nervous system by the kidney. Curr Opin Nephrol Hypertens. 2014;23:61-68. Go to original source...
  4. Guyenet PG. The sympathetic control of blood pressure. Nat Rev Neurosci. 2006;7:335-346. Go to original source...
  5. Hirooka Y, Kishi T, Ito K, et al. Potential clinical application of recently discovered brain mechanisms involved in hypertension. Hypertension. 2013;62:995-1002. Go to original source...
  6. Ryan MJ. An update on immune system activation in the pathogenesis of hypertension. Hypertension 2013;62:226-230. Go to original source...
  7. Esler M. The sympathetic nervous system through the ages: from Thomas Willis to resistant hypertension. Exp Physiol. 2011;96:611-622. Go to original source...
  8. Harrison DG, Guzik TJ, Lob HE, et al. Inflammation, immunity, and hypertension. Hypertension. 2011;57:132-140. Go to original source...
  9. Gelin C, Sloma I, Charron D, et al. Regulation of MHC II and CD1 antigen presentation: from ubiquity to security. J Leukoc Biol. 2009;85:215-224. Go to original source...
  10. Abbas AK, Lichtman AH. Cellular and molecular immunology. 5th ed. Elsevier Saunders: Philadephia, PA, USA: 2005.
  11. Harrison DG, Gongora MC. Oxidative stress and hypertension. Med Clin North Am. 2009;93:621-635. Go to original source...
  12. Madden KS, Sanders VM, Felten DL. Catecholamine influences and sympathetic neural modulation of immune responsiveness. Annu Rev Pharmacol Toxicol. 1995;35:417-448. Go to original source...
  13. Ganta CK, Lu N, Helwig BG, et.al. Central angiotensin II-enhanced splenic cytokine gene expression is mediated by the sympathetic nervous system. Am J Physiol Heart Circ Physiol. 2005;289:H1683-H1691. Go to original source...
  14. Zimmerman MC, Lazartigues E, Sharma RV, et al. Hypertension caused by angiotensin II infusion involves increased super­ oxide production in the central nervous system. Circ Res. 2004;95:210-216. Go to original source...
  15. Abboud FM, Harwani SC, Chapleau MW. Autonomic neural regulation of immune system. Implications for hypertension and cardiovascular disease. Hypertension. 2012;59:755-762. Go to original source...
  16. Zubcevic J, Waki H, Raizada MK, et al. Autonomic-immunevascular interaction: an emerging concept for neurogenic hypertension. Hypertension. 2011;57:1026-1033. Go to original source...
  17. Tracey KJ. The inflammatory reflex. Nature. 2002;420:853-859. Go to original source...
  18. Rahmouni K. Obesity-associated hypertension: Recent progress in deciphering the pathogenesis. Hypertension 2014;64:215-221. Go to original source...
  19. DiBona GF. Sympathetic nervous system and hypertension. Hypertension. 2013;61:556-560. Go to original source...
  20. Gabor A, Leenen FH. Central mineralocorticoid receptors and the role of angiotensin II and glutamate in the paraventricular nucleus of rats with angiotensin II- induced hypertension. Hypertension. 2013;61:1083-1090. Go to original source...
  21. Guild SJ, McBryde FD, Malpas SC, et al. High dietary salt and angio­ tensin II chronically increase renal sympathetic nerve activity: a direct telemetric study. Hypertension. 2012;59:614-620. Go to original source...
  22. Krum H, Sobotka P, Mahfound F, et al. Device-based antihypertensive therapy. Therapeutic modulation of the autonomic nervous system. Circulation 2011;123:209-215. Go to original source...
  23. Fisher JP, Fadel PJ. Therapeutic strategies for targeting excessive central sympathetic activation in human hypertension. Exp Physiol.2 Z 010;95:572-580.